Poster podcasts


Metabolic Bone Disease

Romosozumab after denosumab improves lumbar spine and maintains total hip bone mineral density in postmenopausal women with low bone mass

Michael R McClung, Michael A Bolognese, Jacques P Brown, Jean-Yves Reginster, Bente Langdahl, Norma Ruiz-Santiago, Yifei Shi, Maria Rojeski, Jen Timoshanko, Cesar Libanati, Helina Kassahun and Mary Oates

ACR Convergence 2020 - Poster session - Abs #0101

View
Osteoarthritis and Related Disorders

Observed efficacy with subcutaneous tanezumab is early and maintained in patients with osteoarthritis: results from a 56-week randomized NSAID-controlled study

Tuhina Neogi, David Hunter, Melvin Churchill, Ivan Shirinsky, Masanari Omata, Alexander White, Ali Guermazi, Robert Fountaine, Glenn Pixton, Lars Viktrup, Mark Brown, Christine West and Kenneth Verburg

ACR Convergence 2020 - Poster session - Abs #1642

View
Rheumatoid Arthritis

Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to tumor necrosis factor inhibitors

Roy Fleischmann, Karina Maslova, Henry Leher, Amy Praestgaard

ACR Convergence 2020 - Poster session - Abs #0210

View
Rheumatoid Arthritis

Safety profile of upadacitinib up to 3 years of exposure in patients with rheumatoid arthritis

Stanley Cohen, Ronald F Van Vollenhoven, Jeffrey Curtis, Leonard Calabrese, Cristiano AF Zerbini, Yoshiya Tanaka, Louis Bessette, Casey Schlacher, Tim Shaw, John Liu, Jeffrey Enejosa, Yanna Song and Gerd Burmester

ACR Convergence 2020 - Poster session - Abs #0237

View
Rheumatoid Arthritis

Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 8.4 years: an updated integrated safety analysis

Kevin Winthrop, Tsutomu Takeuchi, Gerd Burmester, Patrick Durez, Walter Deberdt, Douglas Schlichting, Scott Beattie, Daojun Mo, Chad Walls and Josef Smolen

ACR Convergence 2020 - Poster session - Abs #0202

View
Rheumatoid Arthritis

Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: 52-Week Results

Bernard Combe, Alan Kivitz, Yoshiya Tanaka, Désirée van der Heijde, J-Abraham Simon-Campos, Herbert S. Baraf6, Uma Kumar, Franziska Matzkies, Beatrix Bartok, Lei Ye, Ying Guo, Chantal Tasset, John S. Sundy, Angelika Jahreis, Neelufar Mozaffarian, Robert Landewé, Sang-Cheol Bae, Edward C Keystone and Peter Nash

ACR Convergence 2020 - Poster session - Abs #0208

View
Rheumatoid Arthritis

Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 84 weeks

Josef Smolen, Paul Emery, William Rigby, Yoshiya Tanaka, Juan Vargas, Nemanja Damjanov, Manish Jain, Yanna Song, Nasser Khan, Jeffrey Enejosa and Stanley Cohen

ACR Convergence 2020 - Poster session - Abs #0209

View
Rheumatoid Arthritis

Clinical features of patients with active ankylosing spondylitis who did not respond to adalimumab but responded to ixekizumab: a post-hoc analysis

Xenofon Baraliakos, Rebecca Bolce, David Sandoval, Soyi Liu-Leage, Vladimir Geneus, David Adams, Atul Deodhar, Jessica Walsh and Joachim Sieper

ACR Convergence 2020 - Poster session - Abs #1904  

View
Spondyloarthritis Including Psoriatic Arthritis

Impact of HLA-B27 status on clinical outcomes in patients with ankylosing spondylitis treated with secukinumab

Atul Deodhar, Philip Mease, Denis Poddubnyy, Vibeke Strand, Paula Machado, Abhijit Shete, Xiangyi Meng and Marina Magrey

ACR Convergence 2020 - Poster session - Abs #0885

View
Spondyloarthritis Including Psoriatic Arthritis

Bimekizumab improves patient-reported outcomes in psoriatic arthritis: 48-week results from a phase 2b study and association between patient-reported outcomes and disease activity

Laure Gossec, Philip Mease, Alice Gottlieb, Deepak Assudani, Jason Coarse, Barbara Ink and Laura Coates

ACR Convergence 2020 - Poster session - Abs #0356

View
Spondyloarthritis Including Psoriatic Arthritis

Reduction of anterior uveitis flares in patients with axial spondyloarthritis during certolizumab pegol treatment: 96-week results from the c-view study

Irene van der Horst-Bruinsma, Rianne van Bentum, Frank Verbraak, Thomas Rath, James Rosenbaum, Bengt Hoepken, Oscar Irvin-Sellers, Thomas Kumke, Lars Bauer and Martin Rudwaleit

ACR Convergence 2020 - Poster session - Abs #0881

View
Spondyloarthritis Including Psoriatic Arthritis

Efficacy and safety of ixekizumab versus adalimumab with and without concomitant conventional synthetic disease-modifying antirheumatic drugs (DMARD) in biologic DMARD-naïve patients with psoriatic arthritis: 52-week results

Josef Smolen, Anthony Sebba, Eric Ruderman, Amanda Gellett, Christophe Sapin, Aubrey Sprabery, Soyi Liu-Leage, Sreekumar Pillai, Paulo Reis and Peter Nash

ACR Convergence 2020 - Poster session - Abs #0352

View
Spondyloarthritis Including Psoriatic Arthritis

Long-term outcomes with filgotinib, an oral selective janus kinase 1 inhibitor: 100-week data from an open-label extension (OLE) study in patients with active psoriatic arthritis (PsA)

Laura Coates, Dafna Gladman, Filip Van den Bosch, Philip Helliwell, Anna Rychlewska-Hańczewska, Mykola Stanislavchuk, Leen Gilles, Lien Gheyle, Ke Liu, Mona Trivedi, Muhsen Alani, Robin Besuyen and Philip Mease

ACR Convergence 2020 - Poster session - Abs #0907

View
Spondyloarthritis Including Psoriatic Arthritis

Efficacy and safety of deucravacitinib (BMS-986165), an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: results from a phase 2, randomized, double-blind, placebo-controlled trial

Philip Mease, Atul Deodhar, Désirée van der Heijde, Frank Behrens, Alan Kivitz, Jonghyeon Kim, Shalabh Singhal, Miroslawa Nowak and Subhashis Banerjee

ACR Convergence 2020 - Poster session - Abs #L03

View
Spondyloarthritis Including Psoriatic Arthritis

Ustekinumab-treated patients with psoriatic arthritis in a real-world study: similar clinical responses and treatment persistence over one year in elderly and younger patients

Laure Gossec, Elke Theander, Soumya Chakravarty, Paul Bergmans, Iris Lin, Wim Noël, Stefan Siebert and Josef Smolen

ACR Convergence 2020 - Poster session - Abs #0351

View
Spondyloarthritis Including Psoriatic Arthritis

Efficacy of secukinumab treatment in patients with early psoriatic arthritis: a pooled analysis of 4 phase 3 studies

Christopher Ritchlin, Alan Kivitz, Peter Nash, Renato Calheiros, Xiangyi Meng, Corine Gaillez, Bruce Kirkham and Iain McInnes

ACR Convergence 2020 - Poster session - Abs #0889

View
Systemic Lupus Erythematosus

Treatment of SLE with or without nephritis with the immunoproteasome inhibitor KZR-616: updated results of the MISSION study

Richard Furie, Samir Parikh, Kenneth Harvey, Christopher Kirk, Darrin Bomba and MK Farmer

ACR Convergence 2020 - Poster session - Abs #0855

View
Systemic Lupus Erythematosus

Herpes zoster events with anifrolumab in patients with active SLE: an integrated analysis of phase 2 and phase 3 trials

Joan Merrill, Kenneth Kalunian, Richard Furie, Kevin Winthrop, Patricia Primakov, Lilia Pineda, Gabriel Abreu and Raj Tummala

ACR Convergence 2020 - Poster session - Abs #0849

View
Systemic Sclerosis and Related Disorders

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase 3 trial

Dinesh Khanna, Celia J. F. Lin, Helen Spotswood, Jeffrey Siegel, Daniel Furst and Christopher Denton

ACR Convergence 2020 - Poster session - Abs #0396

View